- Home
- RMNI vs YMAB Comparison
RMNI vs YMAB Comparison
Compare RMNI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMNI
- YMAB
- Stock Information
- Founded
- RMNI 2005
- YMAB 2015
- Country
- RMNI United States
- YMAB United States
- Employees
- RMNI N/A
- YMAB N/A
- Industry
- RMNI Business Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RMNI Consumer Discretionary
- YMAB Health Care
- Exchange
- RMNI Nasdaq
- YMAB Nasdaq
- Market Cap
- RMNI 256.4M
- YMAB 270.5M
- IPO Year
- RMNI N/A
- YMAB 2018
- Fundamental
- Price
- RMNI $3.16
- YMAB $5.72
- Analyst Decision
- RMNI Buy
- YMAB Strong Buy
- Analyst Count
- RMNI 2
- YMAB 10
- Target Price
- RMNI $6.00
- YMAB $21.10
- AVG Volume (30 Days)
- RMNI 232.4K
- YMAB 542.6K
- Earning Date
- RMNI 02-27-2025
- YMAB 03-04-2025
- Dividend Yield
- RMNI N/A
- YMAB N/A
- EPS Growth
- RMNI N/A
- YMAB N/A
- EPS
- RMNI N/A
- YMAB N/A
- Revenue
- RMNI $426,650,000.00
- YMAB $84,553,000.00
- Revenue This Year
- RMNI N/A
- YMAB $6.41
- Revenue Next Year
- RMNI N/A
- YMAB $18.15
- P/E Ratio
- RMNI N/A
- YMAB N/A
- Revenue Growth
- RMNI N/A
- YMAB N/A
- 52 Week Low
- RMNI $1.53
- YMAB $5.60
- 52 Week High
- RMNI $3.75
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- RMNI 55.48
- YMAB 35.08
- Support Level
- RMNI $2.73
- YMAB $5.60
- Resistance Level
- RMNI $3.75
- YMAB $6.57
- Average True Range (ATR)
- RMNI 0.20
- YMAB 0.38
- MACD
- RMNI 0.02
- YMAB 0.10
- Stochastic Oscillator
- RMNI 42.16
- YMAB 11.43
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.